Summit Trail Advisors’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.68M Buy
26,697
+7,669
+40% +$534K 0.02% 657
2025
Q4
$1.26M Buy
19,028
+2,068
+12% +$134K 0.02% 680
2025
Q3
$1.14M Buy
+16,960
New +$1.34M 0.02% 753
2024
Q3
Sell
-3,002
Closed -$340K 727
2024
Q2
$340K Sell
3,002
-186
-6% -$23.5K 0.01% 450
2024
Q1
$442K Buy
3,188
+747
+31% +$93.9K 0.01% 363
2023
Q4
$303K Sell
2,441
-461
-16% -$47.1K 0.01% 405
2023
Q3
$271K Sell
2,902
-1,796
-38% -$202K 0.01% 403
2023
Q2
$604K Buy
+4,698
New +$568K 0.02% 232
2018
Q1
Sell
-752
Closed -$11K 770
2017
Q4
$11K Buy
+752
New +$9.78K ﹤0.01% 1190

Other funds holding DXCM

Summit Trail Advisors's DXCM Position: Q1 2026 in Review

Summit Trail Advisors increased its DexCom (DXCM) stake by 40% in Q1 2026, buying an estimated $534K and bringing the position to 26,697 shares worth $1.68M. The position accounts for 0.02% of the portfolio, ranked #657.

Summit Trail Advisors first reported a position in DXCM in Q4 2017 and has held it in 9 quarters since. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Summit Trail Advisors held 26,697 shares of DexCom worth $1.68M as of Q1 2026.
  • Summit Trail Advisors bought 7,669 DexCom shares in Q1 2026, an estimated $534K.
  • DexCom made up 0.02% of Summit Trail Advisors's portfolio in Q1 2026, its #657 holding.
  • Summit Trail Advisors first reported a position in DexCom in Q4 2017 and has held it in 9 quarters since.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.